8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934

Date of Report (Date of earliest event reported):  July14, 2020

LIFELOC TECHNOLOGIES, INC.

(Exact name of registrant as specified inits charter)

(303) 431-9500

(Registrant’s telephone number, includingarea code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Securities registered pursuant to Section 12(b) of the Act:

Item 8.01 Other Events.

On July 14, 2020, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing the results of a study aimed at determining risk of subject to subject virus transmission through select Company products. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.

Item 9.01 FinancialStatements and Exhibits.

(d) Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit 99.1

StudyShows No Detectable Chance of Catching Virus from Breath Alcohol Test

WHEAT RIDGE, Colo., July 14, 2020 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced the results of a study aimed at determining risk of subject to subject virus transmission through their FC Series (Phoenix 6.0, EV30, FC20, etc.) and L Series (LX9, LT7, LT7I) breath alcohol testing products.

“We instinctively know the importance of using a new mouthpiece when conducting a test to prevent cross-contamination. This study confirms the safety of our breath alcohol testing for the person being tested when the test is properly conducted. This is crucial information in the age of Covid-19.” said Director of Sales Amy Evans.

The study, which was commissioned by Lifeloc, simulated a breath alcohol test performed on a highly infected test subject by pumping approximately 2 million MS2 Bacteriophage virus particles through a mouthpiece to simulate an infected subject. The MS2 virus was used in the study as a surrogate for common infectious viruses. After the highly infected test subject simulation, a following breath alcohol test was performed to evaluate risk of cross-contamination on test subjects.

Mark Lary, Director of Regulatory Affairs commented “In the follow up test we used a vacuum pump connected to a BioSampler to create the highest possible risk scenario by actually simulating a subject inhaling for 30 seconds through the mouthpiece. We were determined to see if there was any risk of inhaling a virus from a previous test whether accidently or even through intentional misuse.”

Analysis of the air pulled through multiple mouthpieces found no detectable viruses with the FC Series and L Series units. This analysis was done by an independent test laboratory familiar with testing bioactive hazard risks. Only Lifeloc-brand breath alcohol testers were examined and were demonstrated to not present this risk.

“It is important to Lifeloc that people being tested on our products understand how safe they are,” stated company president Wayne Willkomm. “Lifeloc remains committed to providing safe products for both the operator and the person being tested.”

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

Mark Lary

Lifeloc Technologies, Inc.

http://www.lifeloc.com

(303) 431-9500